



## **Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)**

**The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix rights issue of units announced on September 11, 2023. A total of 54,975,781 Warrants were exercised and consequently the subscription rate was approximately 60.7 percent. Acarix receives approximately SEK 13.7 before issue costs.**

Acarix CEO Aamir Mahmood comments: *"We thank the shareholders who have chosen to exercise their warrants. Your support is very valuable, and it helps us with our mission to transform early cardiac diagnostics by further increasing the availability of our CADScor system. We look forward to managing the trust in the best possible way and work hard every day to deliver shareholder value."*

### **Overview of outcome**

The final outcome indicates that 54,975,781 Warrants were exercised for subscription of shares. The degree of utilization amounted to approximately 60.7 percent. Acarix is provided with approximately SEK 13.7 before issuing costs.

### **Shares and share capital**

By the exercise of the Warrants, the total number of shares in Acarix increases by 54,975,781 to 792,164,597. The share capital in Acarix increases by 549,757.81 SEK to 7,921,645.97 SEK. Exercised Warrants have been replaced with interim shares pending the registration with the Swedish Companies Registration Office ("SCRO"). The interim shares are expected to be converted into shares approximately seven banking days after registration with the SCRO.

### **Advisers**

Penser by Carnegie, Carnegie Investment Bank AB (publ) is acting as financial advisor, and Baker McKenzie is acting as legal advisor to Acarix.

### **IMPORTANT INFORMATION**

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.



This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

**For more information contact:**

Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email [jennifer.anderson@acarix.com](mailto:jennifer.anderson@acarix.com)

**About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

**Attachments**

[Acarix announces the outcome of the exercise of warrants of series 2024:U1 \(TO2\)](#)